|
| 36179268 | Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. | Blood | 2023 |
| 36179268 | Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions. | Blood | 2023 |
| 37977148 | A longitudinal single-cell atlas of treatment response in pediatric AML. | Cancer Cell | 2023 |
| 37693371 | Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. | bioRxiv | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36720638 | Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 37693371 | Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. | bioRxiv | 2023 |
| 37977148 | A longitudinal single-cell atlas of treatment response in pediatric AML. | Cancer Cell | 2023 |
| 37287368 | Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. | Proteomics Clin Appl | 2023 |
| 37019972 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | Nat Commun | 2023 |
| 37267439 | Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. | Blood Adv | 2023 |
| 36789545 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | Pediatr Blood Cancer | 2023 |
| 36815378 | Comprehensive molecular and clinical characterization of <i>NUP98</i> fusions in pediatric acute myeloid leukemia. | Haematologica | 2023 |
| 36720638 | Functional consequence and therapeutic targeting of cryptic ALK fusions in monosomy 7 acute myeloid leukemia. | Pediatr Blood Cancer | 2023 |
| 36689724 | SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. | Blood Adv | 2023 |
| 36634304 | CREBBP alterations are associated with a poor prognosis in de novo AML. | Blood | 2023 |
| 36795987 | Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. | J Clin Oncol | 2023 |
| 35021602 | Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group study. | Haematologica | 2022 |
| 35710794 | Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. | Nat Commun | 2022 |
| 35688939 | A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. | Leukemia | 2022 |
| 36136600 | CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. | J Clin Invest | 2022 |
| 36123353 | Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. | Nat Commun | 2022 |
| 36418348 | Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes. | Nat Commun | 2022 |
| 35021602 | Clinical relevance of proteomic profiling in <i>de novo</i> pediatric acute myeloid leukemia: a Children's Oncology Group study. | Haematologica | 2022 |
| 35176137 | Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. | Blood Cancer Discov | 2022 |
| 35710794 | Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. | Nat Commun | 2022 |
| 35688939 | A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. | Leukemia | 2022 |
| 36418348 | Inflammatory bone marrow signaling in pediatric acute myeloid leukemia distinguishes patients with poor outcomes. | Nat Commun | 2022 |
| 36136600 | CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. | J Clin Invest | 2022 |
| 36123353 | Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. | Nat Commun | 2022 |
| 35176137 | Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. | Blood Cancer Discov | 2022 |
| 32381579 | The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. | Haematologica | 2021 |
| 32381579 | The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. | Haematologica | 2021 |
| 33951732 | CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. | Blood | 2021 |
| 33948920 | Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. | Clin Transl Oncol | 2021 |
| 33938941 | Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. | Blood Adv | 2021 |
| 34793513 | A B-cell developmental gene regulatory network is activated in infant AML. | PLoS One | 2021 |
| 34380639 | Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. | Clin Cancer Res | 2021 |
| 34547772 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | Blood Adv | 2021 |
| 34793513 | A B-cell developmental gene regulatory network is activated in infant AML. | PLoS One | 2021 |
| 34380639 | Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. | Clin Cancer Res | 2021 |
| 34547772 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | Blood Adv | 2021 |
| 33938941 | Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. | Blood Adv | 2021 |